In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
about
Characterization of community-associated Staphylococcus aureus from skin and soft-tissue infections: a multicenter study in ChinaIn vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model.Ceftaroline fosamil: drug profile and clinical data.Ceftaroline fosamil: a brief clinical review.In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.Cutaneous infections and infestations: new therapiesEffects of Subinhibitory Concentrations of Ceftaroline on Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms.Glycopeptide resistance in gram-positive cocci: a review.In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureusIn vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance studyCeftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience.Ceftaroline fosamil: a new broad-spectrum cephalosporin.Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections.Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.Methicillin-resistant Staphylococcus aureus pneumonia in adults.Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study.Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposureEvaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline.Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
P2860
Q28354183-CC2BA499-2A46-4387-8D78-3CEDF0BCA906Q33622755-E5088DD9-03D6-485F-90B9-DC932CC9AAC5Q33772804-8FAD4924-B761-4FD7-8C4A-FFB8B5240AD1Q33939080-07C9BDC3-C5FE-433E-997A-85EBD1ED39B0Q35004919-748F90CC-F015-4B14-AD16-DCB5AB03231FQ35117981-84184942-9040-4FD0-8266-16D2F8520B32Q35542062-74B86A42-A24E-44E3-ABC3-5A96AECDF470Q35628618-5C8C530F-9E17-4CA7-A19C-01872F19DA47Q35901841-C49FC8F4-4B05-4F95-93CB-A86699B78D3CQ36072225-37AB9803-5856-4704-AAB1-9C908AD3F565Q36171604-95D02193-2794-4352-A492-114CF0ADC7F6Q37263425-8C99E652-579A-4253-A1F5-1A503F6D5C09Q37426237-5DA13A37-FE43-4EBB-AD8F-1003D233F440Q37863942-B95F485F-793C-4AFC-88A2-EBEE21D25936Q37947221-D219C553-3F17-4C49-8DDA-EE0DA84E8EAFQ38006689-F6AD8FD6-0D53-4C38-9BF8-B2D16F4C43D3Q38010783-D130FEAF-FC2D-4DD4-B0DC-EE109F421668Q38025132-949948AA-B204-4584-A68D-48814BB7957CQ38061168-62964F26-CA76-4209-BFD3-2A75C993B835Q38117077-749A8C5C-A2F9-4FA1-A4DA-C0155C4427BFQ38185097-6FB2CF25-A102-4835-B2A4-5FB1565C29D6Q38230203-E0176AE0-365E-49E3-B6A1-F62BCC38F8E4Q38262950-D6C158B7-14F8-44D0-84C7-A60B6E1E8BDFQ38425879-D3971325-363A-42C0-978D-FE23283A351BQ38987098-2CC52831-19E8-45FF-A5BF-5CAFC4701FCEQ39484611-51866DC0-06ED-401A-8EBE-EF5AA4B47182Q39682573-34F644D8-ADD6-4B0E-9E4A-B5442797C1FFQ41825567-21D17BE7-B4E9-4ED2-9EC3-2FADCE5FDFC5Q42131112-C0FF5FAC-5446-4710-89A5-C6366D5B5AAAQ42206236-52A5AE38-A69C-475B-8418-60E6CBED98BDQ42275442-F0712528-CB0F-4601-BD44-A9CE46F2332AQ44566052-D46A6CEA-2934-48C3-8EC6-10C3B001F948Q48667274-DE15B736-1149-4F98-9A1B-538FAB11928C
P2860
In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
In vitro activity of ceftaroli ...... taphylococcus aureus isolates.
@en
In vitro activity of ceftaroli ...... taphylococcus aureus isolates.
@nl
type
label
In vitro activity of ceftaroli ...... taphylococcus aureus isolates.
@en
In vitro activity of ceftaroli ...... taphylococcus aureus isolates.
@nl
prefLabel
In vitro activity of ceftaroli ...... taphylococcus aureus isolates.
@en
In vitro activity of ceftaroli ...... taphylococcus aureus isolates.
@nl
P2093
P2860
P356
P1476
In vitro activity of ceftaroli ...... taphylococcus aureus isolates.
@en
P2093
Joan Pawlak
Leonard Johnson
Louis Saravolatz
P2860
P304
P356
10.1128/AAC.01516-09
P407
P577
2010-04-19T00:00:00Z